NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment
LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (Other OTC: NEOL.PK) today announced that it has submitted a Phase II protocol to the FDA for the study of liposome entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally advanced or metastatic pancreatic cancer patients.